Sinopharm Group Valuation
| X2S Stock | EUR 2.50 0.08 3.31% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Sinopharm Group has a current Real Value of €2.39 per share. The regular price of the company is €2.5. Our model measures the value of Sinopharm Group from inspecting the company fundamentals such as Operating Margin of 0.04 %, return on equity of 0.13, and Shares Outstanding of 1.34 B as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Sinopharm Group's price fluctuation is unstable at this time. Calculation of the real value of Sinopharm Group is based on 3 months time horizon. Increasing Sinopharm Group's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Sinopharm stock is determined by what a typical buyer is willing to pay for full or partial control of Sinopharm Group Co. Since Sinopharm Group is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sinopharm Stock. However, Sinopharm Group's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.5 | Real 2.39 | Hype 2.5 |
The real value of Sinopharm Stock, also known as its intrinsic value, is the underlying worth of Sinopharm Group Company, which is reflected in its stock price. It is based on Sinopharm Group's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Sinopharm Group's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Sinopharm Group Co helps investors to forecast how Sinopharm stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sinopharm Group more accurately as focusing exclusively on Sinopharm Group's fundamentals will not take into account other important factors: Sinopharm Group Total Value Analysis
Sinopharm Group Co is at this time estimated to have takeover price of 15.96 B with market capitalization of 7.98 B, debt of 8.42 B, and cash on hands of 34.36 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Sinopharm Group fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
15.96 B | 7.98 B | 8.42 B | 34.36 B |
Sinopharm Group Investor Information
About 51.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.89. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Sinopharm Group last dividend was issued on the 27th of June 2022. Based on the analysis of Sinopharm Group's profitability, liquidity, and operating efficiency, Sinopharm Group Co is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Sinopharm Group Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sinopharm Group has an asset utilization ratio of 155.35 percent. This implies that the Company is making €1.55 for each dollar of assets. An increasing asset utilization means that Sinopharm Group Co is more efficient with each dollar of assets it utilizes for everyday operations.Sinopharm Group Ownership Allocation
Sinopharm Group shows a total of 1.34 Billion outstanding shares. Over half of Sinopharm Group's outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Sinopharm Group. Please watch out for any change in the institutional holdings of Sinopharm Group as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Sinopharm Group Profitability Analysis
The company reported the revenue of 521.05 B. Net Income was 7.76 B with profit before overhead, payroll, taxes, and interest of 44.05 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Sinopharm Group's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Sinopharm Group and how it compares across the competition.
About Sinopharm Group Valuation
The stock valuation mechanism determines Sinopharm Group's current worth on a weekly basis. Our valuation model uses a comparative analysis of Sinopharm Group. We calculate exposure to Sinopharm Group's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sinopharm Group's related companies.Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. The company was founded in 2003 and is headquartered in Shanghai, the Peoples Republic of China. SINOPHARM GRP operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 108370 people.
8 Steps to conduct Sinopharm Group's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Sinopharm Group's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Sinopharm Group's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Sinopharm Group's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Sinopharm Group's revenue streams: Identify Sinopharm Group's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Sinopharm Group's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Sinopharm Group's growth potential: Evaluate Sinopharm Group's management, business model, and growth potential.
- Determine Sinopharm Group's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Sinopharm Group's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Sinopharm Stock analysis
When running Sinopharm Group's price analysis, check to measure Sinopharm Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinopharm Group is operating at the current time. Most of Sinopharm Group's value examination focuses on studying past and present price action to predict the probability of Sinopharm Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinopharm Group's price. Additionally, you may evaluate how the addition of Sinopharm Group to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |